Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Purple Biotech Ltd ADR
(NQ:
PPBT
)
3.110
-0.100 (-3.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Purple Biotech Ltd ADR
< Previous
1
2
Next >
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 10, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
September 18, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 10, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
July 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
July 10, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
July 02, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
July 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
June 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
June 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
April 25, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
March 14, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
February 27, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
February 13, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
December 20, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Fortifies NT219 Patent Protection
November 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
October 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces $5 Million Registered Direct Offering
October 17, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
August 22, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Debuts Scientific Advisory Board
April 25, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
April 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
April 18, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.